{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"MTD was determined as the maximum dose at which fewer than one-third of patients experience Dose Limiting Toxicities (DLT) as assessed by National Cancer Institute (NCI) CTCAE v 4.0 during Cycle 1 of therapy. Gemcitabine was administered on days 1 and 8 of a 21 day cycle at a fixed dose. Brentuximab vedotin was investigated at a starting dose of 1.4 mg/kg administered on day 1 and escalated if tolerated.","groups":[{"description":"Patients receive brentuximab vedotin IV over 30 minutes on day 1 and gemcitabine hydrochloride IV over 100 minutes on days 1 and 8. Treatment repeats every 21 days for up to 15 more courses in the absence of disease progression or unacceptable toxicity. Patients with CR after any course may go off protocol therapy for stem cell transplant.\n\nBrentuximab Vedotin: Given IV\n\nGemcitabine Hydrochloride: Given IV","id":"OG000","title":"Treatment (Brentuximab Vedotin, Gemcitabine Hydrochloride)"}],"paramType":"NUMBER","populationDescription":"The first 9 out of 16 patients enrolled with relapsed/refractory HL in a phase 1 dose finding study of brentuximab vedotin in combination with gemcitabine, were used in determining MTD","reportingStatus":"POSTED","timeFrame":"During cycle 1 of protocol therapy (21 days)","title":"Maximum Tolerated Dose (MTD) for Brentuximab Vedotin","type":"PRIMARY","unitOfMeasure":"mg/kg"}